New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1
Boehringer Ingelheim today announced results from an interim analysis of the SENSCIS®-ON trial evaluating nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). The new analysis was published online as part of ACR Convergence 2020.
SENSCIS-ON is an open-label extension trial to assess the long-term safety of nintedanib in patients with SSc-ILD who completed the Phase III SENSCIS® trial. The study is evaluating the absolute and relative change from baseline in the forced vital capacity (FVC) as a measure of lung function over 52 weeks.1,2
The interim analysis showed that the safety profile of nintedanib in SENSCIS-ON was consistent with that reported over 52 weeks in the SENSCIS trial with diarrhea being the most frequently reported adverse event.1 The analysis showed that 347 patients in the extension study who received nintedanib demonstrated a decrease in FVC over 52 weeks as did patients in the SENSCIS study.1 The average change in FVC from baseline to week 52 of SENSCIS-ON was −51.3 mL in all patients treated in SENSCIS-ON, while the change from baseline to week 52 in the SENSCIS trial was −42.7 mL.1
“Boehringer Ingelheim is continuously committed to providing scientific data, offering clinicians more confidence in treating patients with SSc-ILD,” commented Dr. Susanne Stowasser, Associate Medical Head Pulmonology at Boehringer Ingelheim. “We are thrilled to share the new data demonstrating a similar consistent safety profile of nintedanib in people living with SSc-ILD and suggesting a sustained effect in slowing lung function decline.”
Please click on the link for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/press-release/newanalysisnintedanibsscild
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Media + PR
Tel.: +49 (6132) 77-184531
Mobile: +49 (151) 68948378
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Announces New Data Demonstrating the Positive Anti-inflammatory Effect and Mode of Action of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis6.12.2021 12:00:00 EET | Press release
Galderma today announced that the Journal of Allergy and Clinical Immunology has published gene expression data that demonstrate the positive anti-inflammatory effect and mode of action of nemolizumab in patients with moderate to severe Prurigo Nodularis (PN), confirming the potential of nemolizumab as a major player in the treatment of PN, effectively reducing both pruritus and severity of skin lesions in PN patients. “Transcriptome data is an important step in validating the therapeutic effect of nemolizumab through a deeper understanding of the mode of action at a cellular level. With these data, we are advancing dermatology and contributing to improving our understanding of PN. These data emphasize that nemolizumab may have a key role to play for patients with moderate to severe PN. This will be confirmed by our ongoing nemolizumab Phase 3 studies in PN.” Dr. Baldo Scassellati Sforzolini Global Head of R&D, GALDERMA PN is a rare, potentially debilitating, chronic skin condition wit
iProov and Eurostar Launch Trial to Provide Contactless Travel at London St Pancras International6.12.2021 10:00:00 EET | Press release
iProov, the world leader in biometric face authentication technology, and Eurostar, the high-speed passenger rail service linking the UK with mainland Europe, have announced that their trial of a contactless fast-track service, SmartCheck, is now live. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211205005029/en/ iProov and Eurostar announce contactless travel trial is live at London St Pancras International (Photo: Business Wire) SmartCheck enables passengers to complete secure ticket verification and UK exit check on their mobile devices prior to travel. As part of the trial, Business Premier and Carte Blanche ticket holders will be able to scan their identity documentation using their iPhones before arriving at the station, completing a brief biometric face scan to verify that they are the genuine holder of the identity document. The biometric face verification, which uses iProov’s Genuine Presence Assurance technology,
2021 World Conference on Science Literacy in Focus: Science Literacy for a Green Future6.12.2021 06:53:00 EET | Press release
On November 30, the 2021 World Conference on Science Literacy (WCSL) kick started in Beijing. With the theme of “Science Literacy for a Green Future”, the conference invited esteemed decision-makers, top scientists, renowned scholars, as well as leaders and representatives from key scientific and technological organizations (such as the United Nations Educational, Scientific and Cultural Organization, International Science Council, World Federation of Engineering Organizations, and The World Academy of Sciences for the advancement of science in developing countries). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211205005040/en/ Improving public science literacy and promoting low-carbon green transformation are among the topics they discussed. Together, the attendees shared their ideas, results, and experience of using science for green development, as well as contributing to an effective communication and partnership mecha
Alibaba Group Announces CFO Succession6.12.2021 03:22:00 EET | Press release
Alibaba Group Holding Limited (NYSE: BABA and HKEX: 9988, “Alibaba” or “Alibaba Group”) today announced that Toby Xu, Deputy Chief Financial Officer, will succeed Maggie Wu as the Company’s Chief Financial Officer, effective April 1, 2022. Maggie will continue as a partner in the Alibaba Partnership and serve as an executive director on the Alibaba board. “Maggie has made exceptional contributions that are instrumental to Alibaba’s achievements to date. Since joining Alibaba almost fifteen years ago, Maggie has helped lead three successful company public listings as CFO: Alibaba.com on the Hong Kong Stock Exchange in 2007, and Alibaba Group Holding on the New York Stock Exchange in 2014 and on the Hong Kong Stock Exchange in 2019. She has built and nurtured a finance team with professional capabilities and accomplishments second to none, and has served as our bedrock in pursuing Alibaba’s strategies and business development. Maggie is forever calm and unflappable, regardless of ups and
NextSense Emerges to Unlock Brain Health with Key Partners UCB, Heraeus, UC San Diego, and Emory University3.12.2021 18:00:00 EET | Press release
NextSense, the foundation of brain health, came out of stealth with an announcement made from the AES (American Epilepsy Society) Annual Meeting in Chicago, where NextSense and its partners are presenting the results of their research on seizure detection to peers in academia and industry for the first time. NextSense unlocks brain health with real world data insights and practical, scientific wisdom for daily living. Traditional brain health monitoring technology like EEG machines and polysomnograms are too bulky for home use, requiring patients to stay overnight at hospitals or sleep study clinics for observation. The high cost of care and lack of comfort of these devices makes long-term and continuous monitoring nearly impossible. Not only are these data based on a single timeframe, they observe what is anything but an ordinary night’s sleep. And for anyone living with epilepsy, the unpredictability of seizures makes direct observation and high-quality data-gathering exceedingly rar
Healthcare+ Expo Taiwan to Build an Ecosystem of Digital Transformation in Healthcare3.12.2021 17:15:00 EET | Press release
One of the largest trade fairs in the APAC region- the Healthcare+ Expo Taiwan- takes place on 2 to 5 December in Taipei. The Expo displays Taiwan’s strength in AI, Cloud-based Applications, Flat Panels, IoT and Technologies that make up Metaverse, reflecting the trend on digital transformation in healthcare driven by the global pandemic. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211203005002/en/ Expand Businesses into growing markets in the APAC region, with Healthcare+ B2B. Join medical institutes and companies in the fields of pharmaceuticals, biotechnology, health/ information technology, electronics and manufacturing to promote products, build partnerships and seize supply-demand opportunities. (Graphic: Business Wire) The Expo has an all-star lineup of corporates, including Acer, Asus, AUO, Delta Electronics, Innolux, Quanta and Wistron, demonstrate their technologies and solutions tailored to digital transformati
Eurofins Technologies Launches a New Multiplex RT-PCR Assay for Combined SARS-CoV-2 Screening and Rapid Detection of the Omicron (B.1.1.529) Variant of Concern3.12.2021 16:05:00 EET | Press release
Eurofins Technologies (Paris:ERF) announces the launch of the multiplex RT-PCR assay GSD NovaType Detect + Select K417N SARS-CoV-2. Within just one week since the first reports on the Omicron variant of concern, this kit has been developed as a quick response to identify its presence. The assay is designed for the simultaneous qualitative detection of SARS-CoV-2 genomic RNA and identification of the spike (S) mutation K417N in one reaction. The results of this RT-PCR assay can be obtained within 1 hour, which makes it a fast and cost-effective solution to identifying the presence of the Omicron variant before samples are confirmed by whole genome sequencing. Eurofins Technologies is constantly working to adapt its product offering to meet the challenges of the ongoing COVID-19 pandemic.. For more information, please visit Eurofins Technologies website. About Eurofins Technologies – a fast growing provider of diagnostic technologies in the field of immunoassays and molecular detection m
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom